IL-6 Overview
Molecule Name
Interleukin-6
Synonyms
IL6,Interleukin-6,BSF2,HSF,IFNB2
Drug Development Progress
Drugs in Clinical Trials22
Approved Drugs5
Highest Development StageApproved
Target Synonym
CTL Differentiation Factor，Interleukin 6 (Interferon， Beta 2)，HSF，B-cell stimulatory factor 2，Interferon beta-2，IL6，IFNB2，IL-6，Interleukin-6，Interleukin 6，Hybridoma Growth Factor，IFN-Beta-2，BSF-2，CDF，B-Cell Differentiation Factor，Interferon， Beta 2，Interleukin BSF-2，BSF2，HGF
Background
Interleukin 6 (IL-6) is also known as HGF, BSF2,HSF, IFNB2 and IL-6, originally identified as a B cell differentiation factor, is a multifunctional cytokine that regulates immune responses, hematopoiesis, acute phase responses, and inflammatory reactions.It is secreted by T cells, macrophages , monocytes, fibroblasts,endothelial cells,et.al. to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation. Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. IL-6 is relevant to many disease processes such as diabetes,atherosclerosis, depression,Alzheimer's Disease,systemic,lupus erythematosus,prostate cancer and rheumatoid arthritis. Advanced/metastatic cancer patients have higher levels of IL-6 in their blood.Hence there is an interest in developing anti-IL-6 agents as therapy against many of these diseases.
IL-6 Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Cicatrix; Post-surgical adhesions; Tissue Adhesions | Details |
| Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Arthritis; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Lung Diseases, Interstitial | Details |
| Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | Coronavirus Disease 2019 (COVID-19); Dyslipidemias; Graft vs Host Disease; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Leukemia; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| Ziltivekimab | EX-6018; MEDI-5117; WBP-216; COR-001; NN6018 | Phase 3 Clinical | Medimmune Llc | Anemia; Arthritis, Rheumatoid; Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Heart Failure; Inflammation; Myocardial Infarction; Renal Insufficiency, Chronic | Details |
| Clazakizumab | BMS-645429; ALD518-003; ALD-518; CSL300; BMS-945429; CSL-300 | Phase 3 Clinical | Alder Biopharmaceuticals | Arthritis, Psoriatic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; Cachexia; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cardiovascular Infections; Coronavirus Disease 2019 (COVID-19); Crohn Disease; Diabetes Mellitus; Fatigue; Frailty; Graft vs Host Disease; Inflammation; Kidney Failure, Chronic; Myocardial Infarction; Rejection of organ transplantation; Stomatitis | Details |
| Tabirafusp tedromer | KSI-501ABC; KSI-501 | Phase 3 Clinical | Kodiak Sciences Inc | Diabetic macular oedema; Retinal Diseases; Uveitis; Wet Macular Degeneration | Details |
| Tabirafusp alfa | KSI-101; KSI-501P | Phase 3 Clinical | Kodiak Sciences Inc | Macular Edema | Details |
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics Inc | Alzheimer Disease; Arthritis, Rheumatoid; Brain Injuries, Traumatic; Colitis, Ulcerative; Diabetes Mellitus, Type 2; Insulin Resistance; Parkinson Disease; Post-Acute COVID-19 Syndrome | Details |
| Vamikibart | RO-7200220; RG-6179; EBI-031 | Phase 3 Clinical | Sesen Bio Inc | Diabetic macular oedema; Macular Edema | Details |
| Sodium Hypochlorite | Phase 3 Clinical | Cystic Fibrosis; Dental Pulp Necrosis; Fibrosis; Infections; Pain; Pain, Postoperative; Pulpitis | Details | ||
| Pacibekitug | PF-04236921; TOUR006; TOUR-006; PF-4236921 | Phase 2 Clinical | Pfizer Inc | Arthritis, Rheumatoid; Cardiovascular Diseases; Crohn Disease; Graves Ophthalmopathy; Lupus Erythematosus, Systemic; Renal Insufficiency, Chronic | Details |
| Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid; Asthma; Coronavirus Disease 2019 (COVID-19); Depressive Disorder, Major; Giant Cell Arteritis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Lupus Nephritis; Polymyalgia Rheumatica | Details |
| Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | BIOCAD JSC | Autoimmune Diseases | Details | |
| Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Anxiety; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Depression; Frailty; Hashimoto Disease; Healthy Aging; Inflammation; Sarcopenia | Details |
| FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
| Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
| Tocilizumab biosimilar (Gedeon Richter/Mochida Pharmaceutical) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
| GFS-202-A | GFS-202-A; GFS202A | Phase 1 Clinical | Genfleet Therapeutics (Shanghai) Co Ltd | Cachexia | Details |
| SCD-153 | SCD-153 | Phase 1 Clinical | Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University, Sun Pharma Advanced Research Company Ltd | Alopecia Areata | Details |
| NEX-20A | NEX-20A | Phase 1 Clinical | Nanexa AB | Multiple Myeloma | Details |
| Luxeptinib | CG026806; CG-806; CG’806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc | Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes | Details |
| Wogonin | China Pharmaceutical University, Daewoong Pharmaceutical Co Ltd, Hefei Cosource Medicine Technology, Shandong Buchang Pharmaceuticals Co Ltd | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Luminol sodium | MP-1032 | Approved | Metrio, Selvim | Psoriasis; Immune System Diseases | null | 1997-01-01 | Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Plaque psoriasis; Psoriasis | Details | ||
| Pomalidomide | IMID-4047; CDC-394; CC-4047; IMiD-1 | Approved | Celgene Corp | Imnovid, Actimid, Pomalyst/Imnovid, 安跃, Pomalyst | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2013-02-08 | Anemia, Sickle Cell; Atypical Squamous Cells of the Cervix; Bone Marrow Neoplasms; Carcinoma, Small Cell; Central Nervous System Neoplasms; Glioma; Graft vs Host Disease; Hodgkin Disease; Immunoglobulin Light-chain Amyloidosis; Lung Diseases, Interstitial; Lymphoma, Non-Hodgkin; Medulloblastoma; Multiple Myeloma; Myeloproliferative Disorders; Neurofibromatosis 1; Optic Nerve Glioma; Pancreatic Neoplasms; Plasmacytoma; Polycythemia Vera; Primary Myelofibrosis; Prostatic Neoplasms; Pulmonary Fibrosis; Renal Insufficiency; Sarcoma; Sarcoma, Kaposi; Scleroderma, Systemic; Solid tumours; Thrombocytosis; Waldenstrom Macroglobulinemia | Details |
| Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | United States | Multicentric Castleman's Disease (MCD) | Recordati Rare Diseases Inc | 2014-04-23 | Bone Marrow Neoplasms; Carcinoma, Renal Cell; Castleman Disease; Colorectal Neoplasms; Cytokine Release Syndrome; Diabetes Mellitus, Type 1; Head and Neck Neoplasms; Immunoglobulin Light-chain Amyloidosis; Kidney Neoplasms; Lung Diseases; Lung Neoplasms; Lymphoma, Non-Hodgkin; Monoclonal Gammopathy of Undetermined Significance; Multicentric Castleman's Disease (MCD); Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Ovarian Neoplasms; Pancreatic Neoplasms; Pneumonia; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psychotic Disorders; Rejection of lung transplantation; Respiratory Distress Syndrome, Adult; Respiratory Tract Diseases; Respiratory Tract Infections; Schizophrenia; Smoldering Multiple Myeloma; Thrombocytopenia | Details |
| Andrographolide/Sodium Hydrogen Sulfite | Approved | Bacterial Infections | Details | |||||||
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms | Details |